The inhibition of Panc-1-GR1 cell proliferation and the decrease in the proportion of CD133+ cells by metformin confirmed its potential to increase sensitivity of pancreatic cancer to gemcitabine. Here, PROM1 is linked to pancreatic neoplasm.